Extracellular vesicles for developing targeted hearing loss therapy

J Control Release. 2024 Feb:366:460-478. doi: 10.1016/j.jconrel.2023.12.050. Epub 2024 Jan 11.

Abstract

Substantial efforts have been made for local administration of small molecules or biologics in treating hearing loss diseases caused by either trauma, genetic mutations, or drug ototoxicity. Recently, extracellular vesicles (EVs) naturally secreted from cells have drawn increasing attention on attenuating hearing impairment from both preclinical studies and clinical studies. Highly emerging field utilizing diverse bioengineering technologies for developing EVs as the bioderived therapeutic materials, along with artificial intelligence (AI)-based targeting toolkits, shed the light on the unique properties of EVs specific to inner ear delivery. This review will illuminate such exciting research field from fundamentals of hearing protective functions of EVs to biotechnology advancement and potential clinical translation of functionalized EVs. Specifically, the advancements in assessing targeting ligands using AI algorithms are systematically discussed. The overall translational potential of EVs is reviewed in the context of auditory sensing system for developing next generation gene therapy.

Keywords: Exosomes; Extracellular vesicles; Hearing loss; Inner ear tissue; Targeted delivery.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Artificial Intelligence
  • Deafness*
  • Extracellular Vesicles*
  • Hearing Loss* / genetics
  • Hearing Loss* / therapy
  • Humans